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Abstract: Background: Methicillin-susceptible Staphylococcus aureus (MSSA) is a common pathogen
associated with a range of clinically important infections. MSSA can cause deep-seated infections
requiring prolonged courses of intravenous antibiotic therapy to achieve effective resolution. The move
toward ambulatory or outpatient delivery of parenteral antibiotics has led to an increase in the
use of ceftriaxone as a pragmatic first choice given its advantageous single daily dosing schedule.
Objective: To compare the efficacy of once daily ceftriaxone in the treatment of infections due to
confirmed or suspected MSSA to multiple dosing regimes of anti-staphylococcal antibiotics. Methods:
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts
of Reviews of Effects (DARE), Global Health, PubMed, EMBASE and CINAHL for randomised
controlled trials as well as prospective and retrospective cohort studies that compared ceftriaxone to
any multiple dosing regime of anti-staphylococcal antibiotics. Outcome measures were the proportion
of patients with a resolution of infection based on time after initiation of therapy, adverse reactions,
recurrence and duration of hospital admission. Results: We included two randomized controlled
trials, one prospective observational study and three retrospective cohort studies (643 participants;
246 children, 397 adults). There was no difference in time to resolution of symptoms. The number
of adverse reactions, recurrence of bacteraemia and duration of hospital stay were not significantly
different between ceftriaxone and other anti-staphylococcal antibiotics. Conclusions: Based on a small
number of low-quality studies, ceftriaxone is as effective as multiple dosing regimes for the treatment
of infections due MSSA. An appropriately powered randomized trial is required to demonstrate
equivalence and cost effectiveness.
Keywords: intravenous ceftriaxone; anti-staphlococcal antibiotics; mssa; multiple dosing
1. Background
Staphylococcus aureus is a common pathogen implicated in soft tissue infection, infection of bones
and joints and endocarditis. The severity of infection ranges from localised cellulitis, minor boils or skin
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abscesses to life-threatening systemic infection associated with bacteraemia. Intravenous beta-lactam
antibiotics such as anti-staphylococcal penicillins are recommended as first line treatment for MSSA
infection [1]. The management of S. aureus infection no longer necessitates inpatient admission for
the duration of treatment. Services delivering intravenous antibiotics in the ambulatory care or home
setting are considered credible alternatives to bed based care in patients who do not require organ
system support or intensive physiological monitoring [2]. This approach has the potential to improve
patient experience, reduce harm associated with inpatient admission and reduce costs of care [3].
In order to realise these advantages, changes to standard treatment regimens have been adopted which
minimise the frequency of drug administration.
While anti-staphylococcal penicillin regimens are well established and efficacious treatments in
the management of MSSA infection, the requirement for multiple daily dosing schedules to achieve
adequate therapeutic concentrations is a significant impediment to its use in the home or ambulatory
setting. Ceftriaxone is a third-generation broad-spectrum cephalosporin with in vitro activity against
MSSA [4]. Ceftriaxone is extensively protein bound, resulting in a long elimination half-life that
allows one to only take one daily dosing [3]. Ceftriaxone has become an attractive alternative to treat
confirmed or suspected MSSA and accounts for 18% of all outpatient parenteral antibiotic prescriptions
in Europe [5]. Ceftriaxone administered at a dose of 2 g IV q24 h is recommended by the Infectious
Disease Society of America as a potential first line treatment for native vertebral osteomyelitis and
prosthetic joint infection secondary to MSSA [6]. Ceftriaxone can also be used to treat skin or soft
tissue infections in patients who are deemed to require parenteral antibiotics but are otherwise suitable
for ambulatory or outpatient management [7].
The pharmacokinetic properties of ceftriaxone offer significant practical advantages over other
first line antibiotic regimes targeted at MSSA, but questions remain regarding the efficacy and safety
of this approach. Theoretical concerns have been raised regarding impaired bactericidal activity of
cephalosporins secondary to altered pharmacodynamics caused by an inoculum effect [8]. The use of
ceftriaxone in the initial management of MSSA bacteraemia is controversial given the potential severity
of the condition and the limited available clinical evidence to support its use [9]. A multi-centre
prospective clinical study of 77 patients treated with the narrow-spectrum anti-staphylococcal
cephalosporin, cefazolin, for MSSA bacteraemia, reported an association between the cefazolin-induced
inoculum effect and increased 30-day mortality [10]. Whether these concerns are clinically significant or
generalisable to ceftriaxone is unclear. In addition to concerns regarding efficacy, the use of ceftriaxone
in preference to antibiotics with a narrower spectrum of activity may also contribute to antimicrobial
resistance and increase the risk of Clostridium difficile infection [11].
We performed a systematic review to establish the efficacy of a single daily dose of ceftriaxone for




We included studies of children and adults with suspected methicillin-susceptible S. aureus,
defined by clinical diagnosis, where ceftriaxone was compared to other multiple-dose antibiotic
regimes. We defined multiple-dose regimens as any antibiotic schedule requiring more than one
dose within a 24 h period. The specific type of antibiotic used in the comparator group was not
pre-specified. Studies were included that utilised ceftriaxone across a range of clinical infections.
Microbiological confirmation of MSSA was not a prerequisite for inclusion. While this approach led
to a more heterogenous study population it was felt to more accurately reflect the use of ceftriaxone
in real world practice where antibiotic choice is frequently undertaken in advance of, or in the
absence of identification of a specific pathogen. We excluded trials where a definitive diagnosis of
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methicillin-resistant S. aureus (MRSA) was made, adjunctive therapy was used in one arm and studies
that lacked a comparator or that were conducted in vitro.
We included randomised controlled trials, as well as prospective and retrospective cohort studies
ascertaining the efficacy of ceftriaxone compared to any multiple anti-staphylococcal antibiotic.
We included trials reporting combined interventions if they allowed a direct comparison between
ceftriaxone and any standard anti-staphylococcal antibiotics.
2.2. Outcome Measures
2.2.1. Primary Outcome
The proportion of participants with resolution or improvement of symptoms after initiation of
appropriate therapy.
2.2.2. Secondary Outcomes
Adverse reaction to antibiotics used in the treatment of infections due to S. aureus bacteraemia,
recurrence of bacteraemia within 60 days of discontinuing therapy and the duration of any
hospital admission.
2.3. Search Methods for Identification of Studies
We searched the Cochrane Register of Controlled Trials (CENTRAL 2019, Issue 7), which also
includes the Infectious Diseases (ID) group’s Specialised Register, the Database of Abstracts of Reviews
of Effects (DARE) 2019, Issue 7, on the Cochrane Library (Wiley), Global Health (1973 to July 2019),
PubMed/MEDLINE (OvidSP) (1982 to July 2019), EMBASE (OvidSP) (1974 to July 2019) and CINAHL
(1996 to July 2019). Details of the search strategies are in Supplementary Files 1–5. We conducted follow
up searches relevant to the study using the citation lists of papers identified by the above strategies.
Title, abstract screening and data extraction were performed by one reviewer (MK) and cross checked
by a second reviewer (FM), with disagreements resolved by discussion with a third author (GH).
2.4. Quality Assessment of the Included Studies
Two authors independently assessed the methodological quality of the selected articles. We used
the Cochrane “Risk of bias” tool for randomised controlled trials (RCTs) and the ROBINS-I tool for
assessing the quality of non-randomised studies.
3. Results
We identified 4562 studies (Figure 1). After removal of duplicates, 3143 studies remained,
2930 articles were excluded after title screening and a further 197 articles excluded after abstract
screening. We obtained full-text copies of 16 articles and excluded 10. Of these, one study had clinical
outcome measures different to other studies under review [12]. Three studies used ceftriaxone as an
adjunctive therapy for the treatment of MSSA or did not describe MSSA infections [13–15]. Two studies
were in vitro models [4,16], one [17] lacked a comparator and one study did not use ceftriaxone [18].
Two studies [19,20] assessed a population that presented with pneumonia not demonstrated to be due
to MSSA.
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3.1. Included Studies
We included two randomised controlled trials (RCTs) [21,22], one observational prospective study
and three retrospective cohort studies [23–26]. Two studies were conducted in Australia [22,26] and the
rest [21,23–25] in the USA. In total the studies involved 673 participants (246 children and 427 adults)
investigated or diagnosed with MSSA. See Table 1 for characteristics of included studies.
All included studies assessed the number of participants who had either partial or complete
resolution of signs and symptoms of infection due to suspected or confirmed MSSA infection. Four
studies [22,23,25,26] assessed adverse events and the duration of treatment. Other outcomes assessed
were recurrence of infection necessitating readmission [25,26] and cost of care [22,24–26].
Both randomised controlled trials [21,22] were funded by pharmaceutical companies (Pfizer
Pharmaceutical Company and Roche Products PVT Limited, respectively), and at the time of publication
Roche owned the ceftriaxone patent. Two studies were funded by charitable organisations and
government institutions [24,26] and two studies reported no funding [23,25].
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Table 1. Charicharistics of included studies.
Study Setting Study Type Age of Patients n Intervention/Duration Comparator/Duration Outcome
Kulhanjian et al. 1989 [21] Oakland, CA RCT 2 months–18 years 132 Ceftriaxone 50–70 mg/kg/24 h Ampicillin 15–30 mg/kg/6 h
Resolution of clinical signs and symptoms of infection at the end of
hospitalisation. Absences of recurrence of symptoms on follow up.
Elimination of initial pathogen during therapy. Delayed response
to treatment.
Vinen et al. 1996 [22] Royal North ShoreHospital, Australia RCT 19–61 years 58 Ceftriaxone 1 gram/24 h Flucloxacillin 1 gram/6 h
Complete resolution of all signs and symptoms of infection.
Improvement but without complete resolution of signs and
symptoms. Eradication of causative pathogen.
Ibrahim et al. 2016 [26] MelbourneAustralia
Retrospective
cohort 3 months–18 years 114 Ceftriaxone 50 mg/kg/24 h Flucloxacillin 50 mg/kg/6 h
Treatment failure. Defined as admission from hospital in the home
HITH back to hospital because of inadequate improvement at home
as determined by the treating clinician
Change of antibiotic because of poor clinical improvement. Septic
complication or recurrence during use or within 48 h of I.V.
Adverse events. Death within 28 days Length of hospital stay.
Winans et al. 2013 [25] Houston Texas Retrospectivecohort 18–78 years 122 Ceftriaxone 1 g & 2 g/24 h Cefazolin 2 g/8 h
Favourable clinical outcome-no signs and symptoms of infection.
Complications as a result of infection. readmission to hospital.
Adverse events-nausea/vomiting or diarrhoea, Anaemia,
worsening infection.
Wieland et al. 2012 [24] St Louis Missouri Retrospectivecohort >18 years 124 Ceftriaxone 2 g/24 h Oxacillin 4 g/6 h
Duration of I.V antibiotic.
Resolution of signs and symptoms of infection, Improvement in
inflammatory markers. Complications due to toxicity. Repeat
surgery or readmission.
Patel et al. 2014 [23] Chicago Retrospectivecohort 25–87 years 93 Ceftriaxone 2 g/24 h
Nafcillin/Cefazolin/Vancomycin
41 ± 38 days
Clearance of MSSA bacteraemia. Cure of source and/or complication
of MSSA bacteraemia. No recurrence within 6 months of completion
of I.V therapy. Resolution of signs and symptoms related
to bacteraemia.
Antibiotics 2020, 9, 39 6 of 11
3.2. Risk of Bias in Included Studies (RCTs)
One randomized controlled trial [21] used computer generated randomisation, and the other did
not specify the method [22], see Table 2. The proportions of low, moderate, critical and serious risk of
bias in each domain are illustrated in Figure 2.
Table 2. Risk of bias in the included studies (randomised controlled trials (RCTs)).
Study Allocation Bias Blinding IncompleteOutcome
Selective
Reporting Other Potential Sources








Did not report on the
blinding of outcome







Low risk of bias
Funded by
pharmaceutical company
No declarations of conflict of
interest made.
Vinen et al. 1996 [22]
Details of randomization
not provided
Low risk of bias because
of the nature of the study

















No declarations of conflict of
interest were made
The lack of blinding in the study
posed an issue for allocation.
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We used the ROBINS-I tool [27] to assess the quality of non-randomised studies (Table 3).
Key limitations identified included study design (lack of parallel group randomised trials); use of
cohorts in different clinical settings and age groups (i.e., hospital in the home patients were older and
hospitalised group younger); and potential for confounding of effects due to previous antibiotics prior
to admission. The lack of an objective outcome measure to determine response, combined with the
assessor’s knowledge of treatment allocation was also identified as a consistent source of potential
bias. All studies assessed demonstrated significance in at least one domain.
Table 3. Risk of bias non-randomised studies.
Eligible
Studies




























(2016) [26] Critical Serious Serious Serious
No
Information Serious Serious Critical
Winans et al.
(2013) [25] Moderate Low Moderate Low
No
Information Serious Serious Serious
Wieland et al.
(2012) [24] Low Low Moderate Serious Moderate Moderate Moderate Serious
Patel et al.
(2014) [23] Serious Serious Serious Serious
No
Information Moderate Moderate Serious
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3.3. Effects of Interventions
3.3.1. The Proportion of Participants with Resolution or Improvement of Symptoms
Randomised Controlled Trials
Both RCTs (179 participants—132 children and 47 adults) reported data on the proportion
of resolution or improvement of symptoms. One study [21] compared ampicillin/sulbactam vs.
ceftriaxone while the other [22] compared flucloxacillin vs. ceftriaxone. The follow-up period for
outcome assessment was six months and 48 h–72 h, respectively [21,22]. One study [21] defined a
resolution as the elimination of the initial pathogen during therapy and resolution of clinical signs of
infection at the end of hospitalisation. The other [22] defined a resolution or improvement as complete
resolution of all signs and symptoms of S. aureus bacteraemia after completion of parenteral therapy
at either 48 or 72 h (Table 4). There were no statistically significant differences in improvement or
resolution between the control and intervention groups. Given the variation in outcome assessment
and antibiotics, it was not possible to combine data for these two studies.
Table 4. Outcomes (randomised studies).
Study Duration of Hospital Admission Recurrence within 60 Days ofDiscontinuing Therapy Adverse Reaction to Antibiotics





Kulhanjian et al. 1989 [21] Ceftriaxone 5 days Ampicillin/sulbactam3.5 days (standard deviation not reported)





(1) Ceftriaxone compared to beta lactams:
Two studies [24,26] compared ceftriaxone to flucloxacillin and oxacillin, respectively. Resolution
was defined as resolution of signs and symptoms of infection, improvement in inflammatory markers
and no requirement for readmission at follow-up by one study [24] and as the absence of treatment
failure (hospital readmission because of inadequate improvement at home determined by a clinician)
by the other [26]. Outcome measures were assessed between three and six months in a follow-up visit
and at six months after completion of intravenous antibiotic [24]. Neither study found a significant
difference in the proportion of patients with a resolution of symptoms between ceftriaxone and the
beta-lactam comparator.
(2) Ceftriaxone compared to other anti-staphylococcal antibiotics:
Two studies compared ceftriaxone versus cefazolin, nafcillin or vancomycin [16] and ceftriaxone
versus cefazolin [23,25]. Resolution of staphylococcal infection was defined as a favourable clinical
outcome measured by a physician’s expectations of outpatient parenteral antimicrobial therapy (OPAT)
for MSSA infection [25] or as resolution of signs and symptoms related to bacteraemia, with no
occurrence within six months of completion of antibiotic therapy [23]. Outcome measures were
assessed at three months and 12 months in one study [25] and six months in the other [23]. In both
studies, the proportion of patients experiencing resolution was not significantly different in the
ceftriaxone cohort compared to other anti-staphylococcal antibiotics (Table 5).
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Table 5. Outcomes (cohort studies).
Study Duration of Hospital Admission Recurrence of the Bacteraemia orSymptoms within 60 Days Adverse Reaction
Patel, McKissic et al.
2014 [23]
Ceftriaxone mean 28 days (SD 44);
Nafcillin/cefazolin/vancomycin group mean
36 days (SD 43) (p = 0.41).
Ceftriaxone 11.9% (5/42) standard
antibiotic 11.7 (6/51)
Ceftriaxone 7.1% (3/42) Standard antibiotic
1.9% (1/51)
Ibrahim et al. 2016 [26] Ceftriaxone mean 2.7 days (range 1–10);Flucloxacillin 2.7 days (range 1–8)
Ceftriaxone 4.9% (2/41)
Flucloxacillin 2.9% (3/103) Not reported
Winans et al. 2013 [25] Ceftriaxone median 12 days (range 4–26)Cefazolin median 9 days (range 3–27)
Ceftriaxone 6.8% (3/44) Cefazolin
9.0% (7/78)
Ceftriaxone 2.27% (1/44) Cefazolin 5.1%
(4/78)
Wieland et al. 2012 [24] Not reported Not reported Ceftriaxone 2.7% (2/74) Oxacillin 5% (2/40)
3.4. Secondary Outcomes
3.4.1. Duration of Hospital Admission
Table 4 describes the duration of hospital stay in our two included RCTs [21,22]. No significant
differences were found between ceftriaxone and multiple dosing regimes. Three cohort
studies [23,25,26], found no significant difference in the duration of hospital admission. The remaining
cohort study [24] did not report on this outcome (see Table 5).
3.4.2. Recurrence of the Bacteraemia or Symptoms within 60 Days of Discontinuing Therapy
The three cohort studies which reported this outcome found no differences between ceftriaxone
and other antibiotic groups.
3.4.3. Adverse Reaction to Antibiotics
No significant differences were found in the adverse reactions in the two RCTs. One study [21]
reported mild elevation in blood urea nitrogen and diarrhoea. The other study [22] reported vaginal
candidiasis, nausea and diarrhoea in the ceftriaxone group, and nausea, diarrhoea and abdominal pain
in the flucloxacillin group (see Table 4). In the three cohort studies reporting this outcome, we found
no differences in adverse events between ceftriaxone and the comparator antibiotic (see Table 5).
4. Discussion
4.1. Summary of Main Findings
We found two RCTs and four cohort studies comparing ceftriaxone to multiple dosing regimes
for MSSA infections. Although the definition of resolution differed significantly between studies,
all included studies found no difference in time to resolution of infection, duration of hospital admission,
recurrence of bacteraemia or adverse events when comparing ceftriaxone to multiple dosing regimes.
However, these results are based on a small number of low-quality studies, including small numbers
of participants and using mainly observational designs. The association between ceftriaxone use and
outpatient or ambulatory management creates a selection bias towards less severe illness, which is
likely to favour the intervention.
4.2. Strengths and Limitations
This review performed a comprehensive search of several databases with independent screening,
selection and assessment of eligible articles. The clinical studies included were heterogenous with
significant differences in the primary focus of infection under investigation, the antibiotic regimens
used as comparators and the methodologies and assessment periods used in outcome measurement.
A conscious decision was made to include studies based on the presence of a primary focus of infection
compatible with MSSA infection rather than microbiologically confirmed MSSA infection. We felt
this pragmatic approach best represented the current use of ceftriaxone in clinical practice, where
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MSSA infection is often suspected on clinical grounds but never definitively confirmed. This approach
inevitably resulted in clinical heterogeneity between the included studies.
4.3. Comparison with other Literature
We are not aware of any other systematic review on this topic. Two retrospective cohort studies
not eligible for inclusion in this review demonstrated no clear difference between ceftriaxone and
alternative antibiotics for MSSA [12,18]. A recent meta-analysis comparing ceftriaxone with ceftaroline
or ceftobiprole identified five RCTs and a total of 77 patients with community-acquired pneumonia
secondary to MSSA. Patients treated with ceftriaxone demonstrated higher rates of treatment failure [28].
None of our included studies contained patients with MSSA pneumonia or comparator groups treated
with 5th generation cephalosporins. MSSA pneumonia is relatively uncommon and associated with a
high case fatality [29]. The findings of our study are more relevant to the treatment of suspected MSSA
infections in the ambulatory or outpatient setting.
4.4. Implications for Practice and Research
Based on the limited evidence available, this review suggests that the practice of using ceftriaxone
for the treatment of S. aureus infection is safe and effective when compared to alternative antibiotic
therapies. However, large randomised controlled trials are needed to evaluate the effectiveness of
ceftriaxone compared to multiple doses of anti-staphylococcal antibiotics in the treatment of infections
due to MSSA. Such trials should include measures of symptom improvement and resolution and rates
of representation to healthcare, and should additionally evaluate the cost effectiveness of the two
approaches in settings where ambulatory care is possible.
5. Conclusions
It is imperative that antibiotic selection in the management of MSSA infection is predicated on
strong clinical evidence of efficacy alongside practical considerations surrounding the ideal care setting.
Based on a small number of low-quality studies, ceftriaxone is as effective as multiple dosing regimes
for the treatment of infections due to MSSA. An appropriately powered randomized trial is required to
demonstrate equivalence and cost effectiveness.
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